U.S. markets closed
  • S&P Futures

    4,657.75
    +6.75 (+0.15%)
     
  • Dow Futures

    35,157.00
    +80.00 (+0.23%)
     
  • Nasdaq Futures

    16,405.50
    +14.75 (+0.09%)
     
  • Russell 2000 Futures

    2,250.80
    +10.60 (+0.47%)
     
  • Crude Oil

    70.64
    +0.69 (+0.99%)
     
  • Gold

    1,790.10
    +4.90 (+0.27%)
     
  • Silver

    22.91
    +0.11 (+0.49%)
     
  • EUR/USD

    1.1302
    +0.0009 (+0.08%)
     
  • 10-Yr Bond

    1.5300
    +0.0480 (+3.24%)
     
  • Vix

    22.96
    -5.66 (-19.78%)
     
  • GBP/USD

    1.3321
    +0.0009 (+0.07%)
     
  • USD/JPY

    113.6360
    +0.0280 (+0.02%)
     
  • BTC-USD

    57,236.00
    -242.75 (-0.42%)
     
  • CMC Crypto 200

    1,443.57
    +14.64 (+1.02%)
     
  • FTSE 100

    7,109.95
    +65.92 (+0.94%)
     
  • Nikkei 225

    28,484.88
    +200.96 (+0.71%)
     

Atea Pharmaceuticals to Present at Guggenheim 2nd Annual Vaccines & Infectious Day Conference

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

BOSTON, Sept. 29, 2021 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea together with other members of the Atea management team, will participate in a fireside chat at the Guggenheim 2nd Annual Vaccines & Infectious Day Conference on Tuesday, October 5, 2021 at 9:30 a.m. ET.

A live webcast of the presentation will be available here and on the Company’s website at www.ateapharma.com. A replay of the webcast will be available for 90 days following the presentation.

About Atea Pharmaceuticals

Atea Pharmaceuticals is a clinical stage biopharmaceutical company focused on discovering, developing and commercializing oral therapies to address the unmet medical needs of patients with life-threatening viral diseases. Leveraging the Company’s deep understanding of antiviral drug development, nucleos(t)ide chemistry, biology, biochemistry and virology, Atea has built a proprietary nucleotide prodrug platform to develop novel product candidates to treat single stranded ribonucleic acid, or ssRNA, viruses, which are a prevalent cause of severe viral diseases. Currently, Atea is focused on the development of orally-available, potent, and selective nucleotide prodrugs for difficult-to-treat, life-threatening viral infections, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19, dengue virus, hepatitis C virus (HCV) and respiratory syncytial virus (RSV). For more information, please visit www.ateapharma.com.

Contacts

Jonae Barnes
SVP, Investor Relations and Corporate Communications
617-818-2985
Barnes.jonae@ateapharma.com

Will O’Connor
Stern Investor Relations
212-362-1200
will.oconnor@sternir.com